{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:12:32Z","timestamp":1788437552423,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"discoveric bio alpha ag","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02155-9","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:15:51Z","timestamp":1787404551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer\u2019s brain extracts"],"prefix":"10.1186","volume":"18","author":[{"given":"Eric","family":"Hatterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Broyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Cusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Breve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Batenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuur","family":"Zuidweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Bourguignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Bonnet-Gamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Gueneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Moine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Anceriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Masternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torleif Tollefsrud","family":"Gj\u00f8lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Skjermo","family":"Telstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Calamera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiep","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma D.J.","family":"Van de Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Courade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"1","key":"2155_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","volume":"139","author":"M Colin","year":"2020","unstructured":"Colin M, Dujardin S, Schraen-Maschke S, et al. From the prion-like propagation hypothesis to therapeutic strategies of tauopathies. Acta Neuropathol. 2020;139(1):3\u201325.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2155_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5\u201321.","journal-title":"Nat Rev Neurosci"},{"key":"2155_CR3","doi-asserted-by":"crossref","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging 1995;16(3):271\u20138.","DOI":"10.1016\/0197-4580(95)00021-6"},{"issue":"5","key":"2155_CR4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack CR, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141(5):1517\u201328.","journal-title":"Brain"},{"issue":"4","key":"2155_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"26","key":"2155_CR6","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1016\/j.cell.2025.11.033","volume":"188","author":"JP Courade","year":"2025","unstructured":"Courade JP, Zetterberg Z, H\u00f6glinger G, Dewachter I. The evolving landscape of Alzheimer\u2019s Disease therapy: from Ab to tau. Cell. 2025;188(26):7337\u201354.","journal-title":"Cell"},{"issue":"6","key":"2155_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","volume":"18","author":"AL Boxer","year":"2019","unstructured":"Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549\u201358.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2155_CR8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"2155_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","volume":"136","author":"JP Courade","year":"2018","unstructured":"Courade JP, Angers R, Mairet-Coello G, et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol. 2018;136(5):729\u201345.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2155_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/brain\/awz100","volume":"142","author":"M Albert","year":"2019","unstructured":"Albert M, Mairet-Coello G, Danis C, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142(6):1736\u201350.","journal-title":"Brain"},{"issue":"1","key":"2155_CR11","doi-asserted-by":"publisher","first-page":"14342","DOI":"10.1038\/s41598-023-41382-0","volume":"13","author":"H Geerts","year":"2023","unstructured":"Geerts H, Bergeler S, Walker M, et al. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model. Sci Rep. 2023;13(1):14342.","journal-title":"Sci Rep"},{"key":"2155_CR12","doi-asserted-by":"crossref","unstructured":"Rawal S, Wildsmith KR, Aluri J, et al. An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. Alzheimer Dis Assoc Disord. 2025;39(3):151\u20137.","DOI":"10.1097\/WAD.0000000000000680"},{"issue":"1","key":"2155_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13195-026-02047-y","volume":"18","author":"E Andreozzi","year":"2026","unstructured":"Andreozzi E, Yagi T, Wildsmith K, et al. Etalanetug (E2814) in dominantly inherited Alzheimer\u2019s disease: an open-label phase 1b\/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment. Alzheimers Res Ther. 2026;18(1):87.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"2155_CR14","first-page":"e70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement. 2025;11(2):e70098.","journal-title":"Alzheimers Dement"},{"key":"2155_CR15","unstructured":"Barton MECTAD. 2024. LATE BREAKING SYMPOSIUM 3: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal\u2013mild AD. Presentation 2: Results from TOGETHER, a Phase II study of bepranemab in prodromal\u2013mild AD."},{"issue":"7662","key":"2155_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature. 2017;547(7662):185\u201390.","journal-title":"Nature"},{"issue":"8","key":"2155_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat Med. 2020;26(8):1256\u201363.","journal-title":"Nat Med"},{"issue":"1","key":"2155_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-023-02657-y","volume":"147","author":"BL van der Gaag","year":"2024","unstructured":"Van der Gaag BL, Deshayes NAC, Breve JJP, et al. Distinct tau and alpha-synuclein molecular signatures in Alzheimer\u2019s disease with and without Lewy bodies and Parkinson\u2019s disease with dementia. Acta Neuropathol. 2024;147(1):14.","journal-title":"Acta Neuropathol"},{"key":"2155_CR19","doi-asserted-by":"crossref","unstructured":"Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024 Jan-Dec;16(1):2310890.","DOI":"10.1080\/19420862.2024.2310890"},{"issue":"2","key":"2155_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie K, Barth\u00e9lemy NR, Sato C, et al. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. 2021;144(2):515\u201327.","journal-title":"Brain"},{"issue":"12","key":"2155_CR21","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","volume":"28","author":"K Horie","year":"2022","unstructured":"Horie K, Barth\u00e9lemy NR, Spina S, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022;28(12):2547\u201354.","journal-title":"Nat Med"},{"issue":"9","key":"2155_CR22","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1021\/acschemneuro.9b00217","volume":"10","author":"E Dupr\u00e9","year":"2019","unstructured":"Dupr\u00e9 E, Danis C, Arrial A, et al. Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice Studies. ACS Chem Neurosci. 2019;10(9):3997\u20134006.","journal-title":"ACS Chem Neurosci"},{"key":"2155_CR23","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1038\/s41467-025-58383-4","volume":"16","author":"C Danis","year":"2025","unstructured":"Danis C, Dupr\u00e9 E, Bouillet T, et al. Inhibition of tau neuronal internalization using anti-tau single domain antibodies. Nat Commun. 2025;16:3162.","journal-title":"Nat Commun"},{"key":"2155_CR24","doi-asserted-by":"crossref","unstructured":"Fischer N, Elson G, Magistrelli G, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;12:6:6113.","DOI":"10.1038\/ncomms7113"},{"key":"2155_CR25","doi-asserted-by":"publisher","first-page":"101698","DOI":"10.1016\/j.nicl.2019.101698","volume":"22","author":"LE Jonkman","year":"2019","unstructured":"Jonkman LE, Galis-de Graaf Y, Bulk M, et al. Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. Neuroimage Clin. 2019;22:101698.","journal-title":"Neuroimage Clin"},{"issue":"8","key":"2155_CR26","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JC, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2155_CR27","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.xpro.2020.100054","volume":"1","author":"AC Chlebowski","year":"2020","unstructured":"Chlebowski AC, Kisby GE. Protocol for High-Throughput Screening of Neural Cell or Brain Tissue Protein Using a Dot-Blot Technique with Near-Infrared Imaging. STAR Protoc. 2020;1(2):100054.","journal-title":"STAR Protoc"},{"issue":"12","key":"2155_CR28","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1084\/jem.20160833","volume":"213","author":"JL Guo","year":"2016","unstructured":"Guo JL, Narasimhan S, Changolkar L, et al. Unique pathological tau conformers from Alzheimer\u2019s brains transmit tau pathology in nontransgenic mice. J Exp Med. 2016;213(12):2635\u201354.","journal-title":"J Exp Med"},{"issue":"41","key":"2155_CR29","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","volume":"111","author":"BB Holmes","year":"2014","unstructured":"Holmes BB, Furman JL, Mahan TE, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014;111(41):E4376\u201385.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2155_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402\u201314.","journal-title":"Neuron"},{"issue":"40","key":"2155_CR31","doi-asserted-by":"publisher","first-page":"13812","DOI":"10.1074\/jbc.RA120.012587","volume":"295","author":"J Gu","year":"2020","unstructured":"Gu J, Xu W, Jin N, et al. Truncation of Tau selectively facilitates its pathological activities. J Biol Chem. 2020;295(40):13812\u201328.","journal-title":"J Biol Chem"},{"key":"2155_CR32","first-page":"955","volume":"38","author":"Y Wang","year":"2010","unstructured":"Wang Y, Garg S, Mandelkow EM, et al. Proteolytic processing of tau. Soc Trans. 2010;38:955\u201361.","journal-title":"Soc Trans"},{"issue":"2","key":"2155_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"K Blennow","year":"2020","unstructured":"Blennow K, Chen C, Cicognola C, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain. 2020;143(2):650\u201360.","journal-title":"Brain"},{"issue":"6","key":"2155_CR34","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","volume":"31","author":"K Horie","year":"2025","unstructured":"Horie K, Salvad\u00f3 G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2025;31(6):2044\u201353.","journal-title":"Nat Med"},{"issue":"8","key":"2155_CR35","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29(8):1954\u201363.","journal-title":"Nat Med"},{"issue":"6","key":"2155_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, et al. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97(6):1284\u2013e12987.","journal-title":"Neuron"},{"issue":"4","key":"2155_CR37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3233\/JAD-150962","volume":"51","author":"NR Barth\u00e9lemy","year":"2016","unstructured":"Barth\u00e9lemy NR, Gabelle A, Hirtz C, et al. Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer\u2019s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. J Alzheimers Dis. 2016;51(4):1033\u201343.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2155_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170959","volume":"63","author":"JP Quinn","year":"2018","unstructured":"Quinn JP, Corbett NJ, Kellett KAB, et al. Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. J Alzheimers Dis. 2018;63(1):13\u201333.","journal-title":"J Alzheimers Dis"},{"key":"2155_CR39","doi-asserted-by":"publisher","first-page":"e76494","DOI":"10.7554\/eLife.76494","volume":"11","author":"S L\u00f6vestam","year":"2022","unstructured":"L\u00f6vestam S, Koh FA, van Knippenberg B, et al. Assembly of recombinant tau into filaments identical to those of Alzheimer\u2019s disease and chronic traumatic encephalopathy. eLife. 2022;11:e76494.","journal-title":"eLife"},{"issue":"2","key":"2155_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/2211-5463.13667","volume":"14","author":"T Kimura","year":"2023","unstructured":"Kimura T, Sato H, Kano M, et al. Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers. FEBS Open Bio. 2023;14(2):181\u201393.","journal-title":"FEBS Open Bio"},{"issue":"1","key":"2155_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","volume":"103","author":"JC Augustinack","year":"2002","unstructured":"Augustinack JC, Schneider A, Mandelkow EM, et al. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease. Acta Neuropathol. 2002;103(1):26\u201335.","journal-title":"Acta Neuropathol"},{"key":"2155_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","volume":"Aug","author":"S Wegmann","year":"2021","unstructured":"Wegmann S, Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer\u2019s disease. Curr Opin Neurobiol. 2021;Aug:69:131\u20138.","journal-title":"Curr Opin Neurobiol"},{"key":"2155_CR43","doi-asserted-by":"crossref","unstructured":"Hale G, De Vos J, Davy AD, et al. Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors. Mabs. 2024;16(1):2402701.","DOI":"10.1080\/19420862.2024.2402701"},{"issue":"12","key":"2155_CR44","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/AAC.01285-13","volume":"57","author":"GJ Robbie","year":"2013","unstructured":"Robbie GJ, Criste R, Dall\u2019Acqua WF, et al. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. Antimicrob Agents Chemother. 2013;57(12):6147\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2155_CR45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","volume":"328","author":"G Hale","year":"2024","unstructured":"Hale G. Living in LALA land? Forty years of attenuating Fc effector functions. Immunol Rev. 2024;328(1):422\u201337.","journal-title":"Immunol Rev"},{"issue":"11","key":"2155_CR46","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.4049\/jimmunol.1401218","volume":"194","author":"A Grevys","year":"2015","unstructured":"Grevys A, Bern M, Foss S, et al. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol. 2015;194(11):5497\u2013508.","journal-title":"J Immunol"},{"issue":"1","key":"2155_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys A, Nilsen J, Sand KMK. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621.","journal-title":"Nat Commun"},{"issue":"2","key":"2155_CR48","doi-asserted-by":"publisher","first-page":"103746","DOI":"10.1016\/j.isci.2022.103746","volume":"25","author":"A Grevys","year":"2022","unstructured":"Grevys A, Frick R, Mester S, et al. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience. 2022;25(2):103746.","journal-title":"iScience"},{"issue":"1","key":"2155_CR49","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","volume":"15","author":"S Foss","year":"2024","unstructured":"Foss S, Sakya SA, Aguinagalde L, et al. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024;15(1):2007.","journal-title":"Nat Commun"},{"issue":"1","key":"2155_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s42003-022-03787-x","volume":"5","author":"TT Gj\u00f8lberg","year":"2022","unstructured":"Gj\u00f8lberg TT, Frick R, Mester S, et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun Biol. 2022;5(1):832.","journal-title":"Commun Biol"},{"issue":"1","key":"2155_CR51","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys A, Nilsen J, Sand KMK, et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun. 2018;9(1):621.","journal-title":"Nat Commun"},{"key":"2155_CR52","doi-asserted-by":"crossref","unstructured":"Tuffy KM, Ahani B, Domachowske Joseph B. October. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2\/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY) Vaccine 42. 2024;(24):126276.","DOI":"10.1016\/j.vaccine.2024.126276"},{"issue":"10","key":"2155_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","volume":"227","author":"P Forte-Soto","year":"2023","unstructured":"Forte-Soto P, Albayaty M, Brooks B, Safety. Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. J Infect Dis. 2023;227(10):1153\u201363.","journal-title":"J Infect Dis"},{"issue":"3","key":"2155_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ni.3102","volume":"16","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer\u2019s disease. Nat Immunol. 2015;16(3):229\u201336.","journal-title":"Nat Immunol"},{"issue":"7","key":"2155_CR55","doi-asserted-by":"publisher","first-page":"e5029","DOI":"10.1002\/nbm.5029","volume":"37","author":"NG Smets","year":"2024","unstructured":"Smets NG, Strijkers GJ, Vinje V, Bakker ENTP. Cerebrospinal fluid turnover as a driver of brain clearance. NMR Biomed. 2024;37(7):e5029.","journal-title":"NMR Biomed"},{"issue":"4","key":"2155_CR56","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","volume":"92","author":"SK Kaufman","year":"2016","unstructured":"Kaufman SK, Sanders DW, Thomas TL, et al. Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron. 2016;92(4):796\u2013812.","journal-title":"Neuron"},{"issue":"7880","key":"2155_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y. Structure-based classification of tauopathies. Nature. 2021;598(7880):359\u201363.","journal-title":"Nature"},{"issue":"1","key":"2155_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40478-023-01676-w","volume":"11","author":"B Frey","year":"2023","unstructured":"Frey B, Holzinger D, Taylor K, et al. Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer\u2019s disease brain. Acta Neuropathol Commun. 2023;11(1):181.","journal-title":"Acta Neuropathol Commun"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02155-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:14:09Z","timestamp":1788434049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02155-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All donors signed informed written consent for brain donation and the use of material and clinical information for research purposes. The study was conducted in accordance to the Declaration of Helsinki and the procedures were approved by the local ethical committee of the Amsterdam UMC, Vrije Universiteit Amsterdam (METC number 2009\/148).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Hatterer, Lucile Broyer, Fabien Cusin, Mathieu Clavel, Jeremie Bourguignon, Margot Bonnet-Gamard, Pauline Malinge, Franck Gueneau, Valery Moine, Nadia Anceriz, Krzysztof Masternak and Nicolas Fischer are employees of Light chain Biosciences - Novimmune S.A and received payments from discoveric bio alpha to perform the experiments. Jean-Philippe Courade is employee and stock owner of Discoveric bio alpha. Amsterdam UMC, SAROMICS, Stressmarq, Authera, received payments from discoveric bio alpha to perform the experiments. Wilma D.J. Van de Berg was financially supported by grants from the Dutch Research council (ZonMW 70-73305-98-106; 70-73305-98-102), Alzheimer association (AARF-18-566459), The Michael J. Fox foundation (MJFF-022468; MJFF027187), Parkinson Association (2020-G01), Stichting Woelse Waard (ParKCODE; Nederlands Parkinson Cohort), Horizon Europe (NEUROCOV) and Parkinson Foundation (PF-TRAIL-144386). Wilma D.J. Van de Berg is recipient of \u2018ProPARK\u2019, a public\u2013private partnership receiving funding from ZonMW (40-46000-98-101), Hersenstichting, Parkinson Vereniging, PHARMO Institute NV, Stichting Woelse Waard, Stichting Alkemade-Keuls fonds, CHDR, ABBVIE, Hoffman-La Roche and OccamzRazor. Wilma D.J. Van de Berg received funding for a public\u2013private partnership \u2018CONCERT\u2019 and \u2018ADAPT-PD\u2019 from Health~Holland, Topsector Life Sciences & Health in collaboration with Roche and Genentech. Wilma D.J. Van de Berg performed contract research for Roche Tissue Diagnostics, Discoveric Bio alpha, AC Immune and Gain Therapeutics. All funding has been paid to Amsterdam UMC. Wilma D.J. Van de Berg is a member of the scientific advisory board of Gain Therapeutics, Alzheimer Nederland and PACE Lundbeck Foundation Parkinson\u2019s Disease Research Center. Wilma D.J. Van de Berg is the president of the Dutch association for Parkinson Scientists and member of the board of the Parkinsonalliance Netherlands.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"197"}}